Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) is a pioneering biomedical products company dedicated to enhancing blood safety worldwide. The company’s flagship technology, the INTERCEPT Blood System, aims to mitigate the risk of transfusion-transmitted diseases by inactivating a broad spectrum of pathogens, including viruses, bacteria, and parasites present in donated blood. Utilizing a unique nucleic acid targeting mechanism, the INTERCEPT system offers protection against established threats like Hepatitis B and C, HIV, West Nile Virus, and bacteria, while also being designed to inactivate emerging pathogens such as Influenza, Malaria, and Dengue.
Cerus Corporation markets and sells the INTERCEPT Blood System for both platelets and plasma in various regions including Europe, Russia, the Middle East, and selected countries globally. The INTERCEPT Red Blood Cell system is currently in clinical development, highlighting the company’s ongoing efforts to broaden its product offerings and enhance blood safety further.
Recent achievements for Cerus include expanding market reach, securing regulatory approvals, and forging key partnerships to strengthen its global presence. Financially, Cerus remains focused on sustaining growth through innovation and strategic collaborations.
By prioritizing safety and efficacy, Cerus Corporation plays a critical role in the field of blood transfusion safety, making significant strides in protecting public health on a global scale.
Cerus Corporation (Nasdaq: CERS) reported a strong second quarter of 2021, achieving total revenue of $37.8 million, a 41% year-over-year increase. Product revenue rose to $31.5 million, up 46% from 2020, driven by demand for INTERCEPT platelet products. The company has raised its annual product revenue guidance to $118-$122 million, marking a projected 28%-33% growth over 2020. Despite a net loss of $15.4 million for the quarter, the firm maintains healthy cash reserves of $123 million as of June 30, 2021.
Cerus Corporation (Nasdaq: CERS) announced that CMS has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex under the Medicare Hospital Inpatient Prospective Payment System (IPPS). The NTAP, applicable for patients with massive bleeding due to fibrinogen deficiency, allows additional payment of up to $2,535 per patient when costs exceed the MS-DRG payment. This decision supports improved access to this innovative blood product, enhancing care in urgent situations. The INTERCEPT Blood System for Cryoprecipitation received FDA Breakthrough Device designation and was approved in November 2020.
Cerus Corporation (Nasdaq: CERS) is set to release its second quarter 2021 financial results on August 3, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET, where management will discuss the financial outcomes and provide a business outlook. Investors can access the call via the Cerus Investor Relations website or through dedicated phone lines for U.S. and international participants. The replay will be available until August 17, 2021. Cerus is focused on enhancing blood safety through its INTERCEPT Blood System, with products approved in multiple regions.
Cerus Corporation (NASDAQ: CERS) has partnered with LifeSouth Community Blood Centers to produce INTERCEPT® Fibrinogen Complex, expanding its initial commercial launch into Florida. This addition marks LifeSouth as the fifth production partner, enhancing distribution capabilities to over one-third of the U.S. population, which includes Florida's significant healthcare infrastructure. Anticipated BLA approvals are set to support a nationwide launch in 2022. The initiative aims to address the critical needs for blood management in transfusion medicine.
Cerus Corporation (Nasdaq:CERS) has signed a contract with Canadian Blood Services to implement the INTERCEPT Blood System for Platelets, marking its entry into the Canadian market. The initial rollout will begin in the Ottawa region in Fall 2021, pending Health Canada approval, with plans for broader implementation after extending the shelf life of pathogen-reduced platelets. Canadian Blood Services aims to manufacture approximately 115,000 platelet doses annually, focusing on minimizing transfusion-transmitted infections.
Cerus Corporation (Nasdaq: CERS) reported first-quarter 2021 revenue of $29.6 million, a 20% increase from $24.6 million in Q1 2020. Product revenue grew by 26% to $23.4 million, driven by heightened demand for INTERCEPT platelet products in the U.S. The company raised its annual product revenue guidance to $110-$114 million, indicating a 20%-24% growth from 2020. Gross margins decreased to 52.5% from 55.3% due to product mix changes. The net loss was $17.5 million, with operational cash usage narrowing to $18 million. Cash reserves stood at $132 million by March 31, 2021.
Cerus Corporation (Nasdaq: CERS) will release its Q1 2021 financial results on May 4, 2021, after market close. A conference call will follow at 4:30 P.M. ET for management to discuss the results and provide a business outlook. Interested parties can access the webcast through the company's Investor Relations page or join the call via designated phone numbers. Cerus focuses on enhancing blood safety and has developed the INTERCEPT Blood System, which is the only pathogen reduction technology with both CE mark and FDA approval for platelets and plasma.
Cerus Corporation (Nasdaq: CERS) announced that CEO William ‘Obi’ Greenman and CFO Kevin D. Green will participate in the Jefferies Virtual Global Plasma Summit on March 11, 2021, at 11:00 am PT/2:00 pm ET.
A live webcast will be available on the Cerus Investor Relations page, with a replay accessible for two weeks post-event. Cerus focuses on safeguarding the global blood supply with its INTERCEPT Blood System, which is the only pathogen reduction system for platelets and plasma approved by both CE and FDA. The red blood cell system is currently under regulatory review in Europe.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
What is Cerus Corporation's main focus?
What pathogens does the INTERCEPT Blood System target?
Where is the INTERCEPT Blood System marketed?
What products does Cerus Corporation offer?
What are some recent achievements of Cerus Corporation?
How does the INTERCEPT Blood System work?
What financial strategies does Cerus Corporation employ?
Is Cerus Corporation involved in research for emerging pathogens?
What regions are key markets for Cerus Corporation?
What segment does Cerus Corporation operate in?
